Recognized as an oncogene, PREX2 displays abnormal expression in various tumors, with mutations or abnormal expression observed in melanoma [14], breast [15], ovarian [15], prostatic [15], hepatocellular carcinoma [16], and pancreatic cancer [17]. Here, PREX2 is linked to hepatocellular carcinoma.